2001
DOI: 10.2169/internalmedicine.40.845
|View full text |Cite
|
Sign up to set email alerts
|

Cabergoline, a Hopeful Medicine for Prolactinomas and Non-tumoral Hyperprolactinemia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2004
2004
2004
2004

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 8 publications
0
1
0
Order By: Relevance
“…Cabergoline is a long-lasting, ergot derivative, selective dopamine D2 receptor agonist that has been used effectively in the treatment of both microprolactinomas and macroprolactinomas. [21][22][23]29,35,48,49,89,94 Although more expensive than bromocriptine, cabergoline is associated with less frequent and less severe side effects. This drug appears to be superior to bromocriptine in normalizing prolactin levels, restoring gonadal function, and decreasing the size of the tumor.…”
Section: Cabergoline and Other Dopamine Agonistsmentioning
confidence: 99%
“…Cabergoline is a long-lasting, ergot derivative, selective dopamine D2 receptor agonist that has been used effectively in the treatment of both microprolactinomas and macroprolactinomas. [21][22][23]29,35,48,49,89,94 Although more expensive than bromocriptine, cabergoline is associated with less frequent and less severe side effects. This drug appears to be superior to bromocriptine in normalizing prolactin levels, restoring gonadal function, and decreasing the size of the tumor.…”
Section: Cabergoline and Other Dopamine Agonistsmentioning
confidence: 99%